111 KB27 KB192920262003Černelč, Peterštevilka:4letnik:72str. 201-204ISSN:1318-0347COBISSID_HOST:16259033URN:URN:NBN:SI:doc-RBO5NTIMslSlovensko zdravniško društvoZdravniški vestnikAdultAntineoplastic Agents, CombinedAntineoplastiki sestavljeniBone Marrow TransplantationDeksametazonDexamethasoneDiagnosisInterferon-alfaInterferon-AlphaKostni mozeg, presaditevLeukemia, PlasmacyticLevkemija s plazmatkamiOdrasliTherapyVincristineVinkristinZdravljenje primarne plazmacelične levkemije| Treatment of primary plasma cell leukemia|Background. The author describes long-term survival in 3 patients with primaryplasma cell leukaemia (PL) after different therapeutic regimen and maintenance treatment with interferon alpha (INF). Patients and treatment. In a 52 year-old male patient, a partial remission of PL was achieved after 6 months of treatment with melphalan and prednisone. The patient did not consentto stem cell transplantation (SCT). An 86 year-old female patient with PL achieved a complete remission after 6 months of treatment with vincristine,doxorubicin and dexamethasone. A 31 year-old male patient experienced a complete remission of PL after 6 months of treatment with cyclophosphamide, vincristine, doxorubicin, methilprednisone, followed by autologous SCT. All three patients were placed on maintenance therapy with INF-2b(IntronA)3 X 106IU given subcutaneously on two days per week. In the 52 year-old man, the remission lasted 9 months and in the woman 23 months, where upon they developed a relapse with signs of disseminated plasmacytoma. In bothpatients the former chemotherapy was applied again, resulting in a slight improvement. The man died 37 months and the woman 43 months after the diagnosis of PL, while the youngest patient has been in complete remission for82 months. Conclusions. Long remission achieved in ourpatients confirmed the favourable effect of INF in terms of prolongation of the remission duration in this patients. The effect of maintenance treatment with INF is usually directly dependent on the degree of remission induced by different therapeutic regimenIzhodišča. Avtor opisuje dolge remisije bolezni po različnih načinih zdravljenja s citostatiki in enakim vzdrževalnim zdravljenjem z interferonom alfa-2b (INF) pri treh bolnikih s primarno plazmacelično levkemijo (PL). Bolniki in zdravljenje. Pri 52-letnem bolniku smo po šestih krogih zdravljenjaz melfalanom in prednizonom dosegli delno remisijo bolezni. Za presaditev krvotvornih matičnih celic (KMC) se bolnik ni odločil. Pri 86-letnibolnici smo dosegli popolno remisijo bolezni po šestih krogih zdravljenja z vinkristinom, doksorubicinom in deksametazonom. Pri 31-letnem bolniku smo dosegli popolno remisijo bolezni po šestih krogih zdravljenja s ciklofosfamidom, vinkristinom, Adriablastinom in metilprednizolonom, ki mu je sledila avtologna presaditev KMC. Vzdrževalno zdravljenje smo pri vseh treh nadaljevali z INF 3 X 106 IE dvakrat na teden. Pri 52-letnem bolniku smo ugotovili po devetih, pri bolnici pa po 23 mesecih poslabšanje bolezni. Pri obeh bolnikih smo z enako kombinacijo citostatikov dosegli kratkotrajno delno izboljšanje bolezni. Bolnik je umrl 37 mesecev, bolnica pa 43 mesecev po ugotovitvi bolezni, medtem ko je najmlajši bolnik 82 mesecev v popolni remisiji bolezni. Zaključki. Vzdrževalno zdravljenje z INF podaljša remisijo PL. Trajanje remisije je sorazmerno s stopnjo dosežene remisije po zdravljenjus citostatikiTEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaSlovensko zdravniško društvo